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Abstract
The characterisation of risk factors for fracture that contribute significantly to fracture risk, over 
and above that provided by BMD, has stimulated the development of risk assessment tools. The 
more adequately evaluated tools, all available online include the FRAX® tool, the Garvan fracture 
risk calculator and, in the UK only, QFracture®. Differences in the input variables, output and 
model construct give rise to marked differences in the computed risks from each calculator. 
Reasons for the differences include the derivation of fracture probability (FRAX) rather than 
incidence (Garvan, QFracture), limited calibration (Garvan) and inappropriate source information 
(QFracture). These differences need to be taken into account in the evaluation of assessment 
guidelines.
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Introduction
A significant advance over the past 15 years has been the development of medical 
interventions that have been shown in high quality randomised controlled trials to decrease 
the risk of fragility fractures [1, 2]. Unfortunately, a minority of men and women receive 
treatment even after sustaining a fragility fracture [1, 3]. The reason for a large treatment gap 
(the difference between the number of individuals at high risk and the proportion of the 
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population that receives treatment) is complex and multifactorial. One of the reasons is, 
however, limitations in the assessment of fracture risk.
Although the diagnosis of the disease relies on the quantitative assessment of bone mineral 
density (BMD), a major determinant of bone strength, the clinical significance of 
osteoporosis lies in the fractures that arise. The causation of fractures is, however 
multifactorial. In this respect, there are some analogies with other multifactorial chronic 
diseases. For example, hypertension is diagnosed on the basis of blood pressure whereas an 
important clinical consequence of hypertension is stroke, the likelihood of which is 
dependent on multiple fractures including hypertension.
Despite many guidelines using BMD thresholds to determine whether treatments should be 
recommended, the multifactorial nature of fracture risk means that BMD does not capture 
non-skeletal determinants of fracture risk such as liability to fall. A number of risk factors 
for fracture has been identified that contribute significantly to fracture risk over and above 
that provided by BMD [4]. A good example is age where the same BMD has a different 
significance at different ages, such that fracture risk is much higher in the elderly than in the 
young [5, 6]. This is because age contributes to risk independently of BMD. The realisation 
that independent risk factors in combination with BMD predict fractures with greater 
accuracy than BMD alone [4] has led to the development of risk prediction tools to better 
categorise individuals at high or low risk and, in turn to optimise clinical decision making 
with regard to therapeutic intervention. This paper reviews the strengths and weaknesses of 
the most commonly espoused risk assessment tools.
Fracture risk prediction tools
Several assessment tools have been derived most of which have been poorly validated [7, 8]. 
The more adequately evaluated tools, all available online include the FRAX® tool [7], the 
Garvan fracture risk calculator [9, 10] and, in the UK, QFracture® [11, 12].
FRAX
The FRAX algorithm is based on a series of meta-analyses of data from 12 independent 
fracture studies from North America, Europe, Asia, and Australia [13–18], which comprised 
a total of 60,000 men and women with more than 250,000 person-years of follow-up, and 
included more than 1100 cases of hip fracture and 3300 osteoporotic fractures [7].
After the fracture risk algorithm had been constructed using primary data from these studies, 
a validation study was performed using individual-level data from 11 independent 
population-based cohorts that were not used in the development of the original model [19]. 
The latter comprised a total of 230,000 individuals with more than 1.2 million person-years 
of follow up. By reason of its large numbers, its international character, and the care taken in 
its construction and implementation, the FRAX algorithm is considered to have unique 
authority [20]. The algorithm provides information on the 10-year probabilities of hip 
fracture and any major osteoporotic fracture (defined as a hip, wrist, humerus, or clinical 
vertebral fracture). Further details are provided in an accompanying paper in this volume.
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QFracture
The QFracture tool is based on a UK prospective open cohort study of routinely collected 
data from 357 general practices on over 2 million men and women aged 30-85 years 
(www.qfracture.org) [11]. Like the FRAX tool it takes into account history of smoking, 
alcohol, corticosteroid use, parental history (of hip fracture or osteoporosis) and several 
secondary causes of osteoporosis. Unlike FRAX it also includes a history of falls (yes/no 
only over an unspecified time frame), utilises a large number of clinical risk factors and no 
provision is made for BMD. It has been internally validated (i.e. from a stratum of the same 
population), and externally validated in a similar population (routinely collected data in 
general practitioner records). The performance characteristics and calibration in the UK have 
been compared with FRAX with comparable results for hip fracture. The tool is not 
calibrated to the epidemiology of other countries. A feature of QFracture is that it is more 
cumbersome (more questions), and does not accommodate the inclusion of BMD. BMD 
measurements are dismissed as “expensive and inconvenient tests” [11] and so the model 
ignores a wealth of data demonstrating the utility of BMD testing in fracture risk 
assessment.
Garvan
The Garvan tool (www.garvan.org.au) is based on many fewer men and women from a 
single study, the Australian Dubbo Osteoporosis Epidemiology Study (DOES) of 
approximately 2500 men and women age 60 years or more. It differs from FRAX by 
including a history of falls (categorised as 0, 1, 2, >2 in the previous year), and the number 
of previous fragility fractures (categorised as 0, 1, 2, >2), but does not include other FRAX 
variables such as parental history of hip fracture, secondary osteoporosis, rheumatoid 
arthritis, glucocorticoid use, smoking and intake of alcohol. The output of the tool differs 
from FRAX in that it reports the risk of a larger number of fracture sites (additionally 
includes fractures of the distal femur, proximal tibia/fibula, distal tibia/fibula, patella, pelvis, 
ribs sternum, hands and feet excluding digits). Further details are provided in an 
accompanying paper in this volume.
Comparative features
There are important differences in the input variables, output and model features that make 
comparison of the models problematic. A summary of input variables is given in Table 1.
With regard to input variables, both Garvan and QFracture include a history of falls whereas 
this is not an input variable in FRAX. Indeed the Garvan tool weights the number of falls in 
the past year. Whereas falls are a strong risk factor for fracture, the incorporation of falls into 
FRAX is problematic for several reasons. First, at the time of the release of FRAX, existing 
falls data were not of adequate quality, including the heterogeneous construct of questions 
on falls. Second, falls risk is inherently taken into account in the algorithm, though not as an 
input variable. Thus, the fracture probability given for any combination of risk factors 
assumes that the falls risk is that observed (but not documented) in the cohorts used to 
construct FRAX. Third, the interrelationship of falls risk with the other FRAX variables has 
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been inadequately explored on an international basis. Fourth, the relationship between the 
risk variable and mortality needs to be accounted for, but there are no data available.
These technical problems aside, risk assessment tools are intended to identify a risk that is 
amenable to a therapeutic intervention. However, falls as a risk variable does not consistently 
pass the test of reversibility of risk [21–23], a necessary feature of any risk variable used in 
in tools to direct interventions [7, 24]. Recently, an analysis in elderly men, available as a 
meeting abstract, indicated that the predictive value of falls for fracture waned significantly 
with time [25]. If the phenomenon is replicated more generally, then this would further 
question the utility of falls history in the long term (e.g. 10-year) assessment of fracture risk. 
Thus, a useful role of falls history in fracture risk assessment remains sub judice. There are 
also few data that many of the QFracture risk factors (cardiovascular disease, type 2 
diabetes, asthma, tricyclic antidepressants usage, history of falls or liver disease) 
characterises a risk that is amenable to bone-targeted interventions.
Other important differences between models include the question construct for fracture 
history given as past fragility fracture (for FRAX), fractures since the age of 50 years 
(Garvan) or past wrist, spine, hip or shoulder fracture (QFracture). For BMD, the femoral 
neck is the reference site for FRAX and for Garvan but is not an input variable for 
QFracture.
Important differences in the output and model features are given in Table 2. The Garvan 
instrument includes many more fracture outcomes than QFracture or FRAX. Compared with 
FRAX, the inclusion of these additional fractures is expected to inflate fracture risks in 
women by 34-45% depending on age [26].
The outcome variable differs between models, not only in the fracture sites but also in the 
metric. In the case of FRAX, the algorithm computes a fracture probability (i.e. a metric that 
incorporates the death hazard) which is not synonymous with simple fracture incidence. This 
is illustrated in Figure 1 that shows the difference in outcome between hip fracture 
probability as estimated by FRAX and incidence calculated using the Garvan instrument. As 
a result, the comparisons are problematic [27].
Comparison of output
A comparison of the performance characteristics of the three models is beyond the scope of 
this review, but for hip fracture risk appear to be rather comparable [28] taking into account 
the methodological flaws in most of the comparative studies [27]. Given the considerations 
above, it is not surprising that each model identifies different segments of populations at 
high risk. Of equal importance is that very different estimates are derived in single 
populations. For example, the three models were compared in a referral population from 
Denmark. For hip fracture prediction, the mean 10-year risk (with interquartile range) was 
11.0% (5.6-17.0%) for FRAX, 14.5% (7.3-23.0%) for QFracture and 26.4% (10.4-53.3%) 
for Garvan [29]. Irrespective of the model constructs, these differences are not surprising 
given that neither QFracture nor Garvan are calibrated for the country in which they were 
used.
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When QFracture and FRAX are applied to the UK population, there is reasonable 
concordance for hip fracture risk since both are calibrated to the UK, though in different 
ways. The Garvan instrument is calibrated only to Dubbo and is the outlier (Figure 2). The 
concordance of the Garvan and FRAX tools reported in Canada [30] is thus a fortuitous 
accident occasioned by the similar epidemiology between Canada and Dubbo. The claim of 
good calibration in Norway is not supported by the evidence [31].
Whereas QFracture and FRAX are comparably calibrated for hip fracture risk [11, 12], a 
quite different pattern is evident for major osteoporotic fractures where the probabilities 
derived from FRAX are markedly higher than the incidences from QFracture. The Garvan 
instrument gives even higher values as shown in Figure 3 for the same clinical scenarios as 
in Figure 2. The Garvan tool provides the highest risks, in part because the output is the 10-
year incidence of all fractures (minus those at the digits). QFracture gives the lowest 
estimates. This is confirmed in Figure 4 where the 10-year hip fracture rates/probabilities are 
shown in women at each decile of risk category [32, 33, 34].
The reason for the discrepancy is that QFracture is derived from General Practitioner records 
that are often incomplete for some important variables [34]. For example, GP records are 
reasonably accurate for the documentation of hip fracture but notoriously unreliable for 
other major fractures, particularly vertebral fractures [35]. Thus, the prevalence of a prior 
major fracture in the QFracture data base is 1.9% [12], whereas prior fracture is estimated at 
21-45% in women from the UK, depending on age [36]. Of these, approximately half will be 
major fractures. For a parental history of osteoporosis or hip fracture the prevalence is given 
at 0.3% in the QFracture data base whereas meta-analysis of prospective studies gives a 
prevalence of parental hip fracture at 13% [15]. The impact of the inaccuracies is difficult to 
quantify but is likely to decrease the median of the distribution of 10-year risk in the 
population. Empirical observation supports this view in that at each tenth of risk category, 
QFracture risk is lower than FRAX-based probabilities (see Figure 4).
The poor and inaccurate capture of clinical risk factors is likely to bias the weights for both 
hip fracture risk and major fracture risk. In the case of FRAX and Garvan, the probability of 
fracture is approximately doubled with a prior history of fracture consistent with worldwide 
observation [13, 37]. In the case of major fracture incidence, QFracture determines an 
increase in risk ratio of approximately only 8%, rather than the expected doubling of risk 
[34]. As expected from meta-analysis, the impact of a prior fracture is somewhat greater at 
younger ages [13] and is accommodated in FRAX. In contrast, the weighting given for a 
prior fracture as a risk fracture is unrealistic for QFracture and does not vary with age (the 
latter, also the case for Garvan).
A further problem arises in considering the pattern of fractures with age. As expected, 
FRAX probabilities of a major fracture exceed that of hip fracture at all ages. In the case of 
QFracture the incidence of hip fracture and the incidence of major fracture are identical 
from the age of 85 years. This implies that no fractures of the spine, humerus or distal 
forearm arise in women from the age of 85 years. Again, this contrasts with empirical 
observation [26, 38, 39]. Indeed, fragility fractures other than hip fracture account for 
64-67% of fractures in women and men (respectively) aged 85-89 years [26].
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These considerations indicate that little credence can be afforded for estimates of major 
fracture using the QFracture algorithm. They further indicate that the weights given to 
several of the clinical risk factors are inappropriate. Both factors result in a large 
underestimation of major fracture risk by QFracture. In contrast, the prevalence and weight 
of clinical risk factors, and the pattern of fractures with age of major fractures has been 
extensively validated with the use of FRAX [26, 38–41]. In summary, FRAX is well 
calibrated whereas QFracture under-predicts the risk of major fractures at all levels of risk.
Conclusion
There are important differences between the FRAX tool, the Garvan fracture risk calculator 
and QFracture® that make their comparison problematic. Differences in the input variables, 
output and model construct give rise to marked differences in the computed risks from each 
calculator. Reasons for the differences include the derivation of fracture probability (FRAX) 
rather than incidence (Garvan, QFracture), poor calibration (Garvan) and inappropriate 
source information (QFracture).
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Figure 1. 
The risk of hip fracture with age in a model that considers 10-year fracture risk alone (the 
Garvan tool) and FRAX which computes the probability of hip fracture from the fracture 
and death hazards (FRAX). The T-scores are set differently in the two models so that the 
risks are approximately equal at the age of 60 years. Data are computed from the respective 
web sites. [27] with kind permission from Springer Science+Business Media B.V]
Kanis et al. Page 9
J Clin Densitom. Author manuscript; available in PMC 2018 January 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2. 
Comparison of the risk of a hip fracture using the Garvan calculator, FRAX and QFracture 
in women with a prior fracture from the UK by age. Height was set at 165cm (QFracture and 
FRAX) and weight at 65kg (all models).
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Figure 3. 
Comparison of the risk of any fragility fracture using the Garvan calculator, and the risk of a 
major osteoporotic fracture with FRAX and QFracture in women with a prior fracture from 
the UK by age. Height was set at 165cm (QFracture and FRAX) and weight at 65kg (all 
models).
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Figure 4. 
Comparison of the distribution of FRAX and QFracture (QF) model output by decile of risk 
in women for hip fracture (left panel [12] and major fracture (right panel) [33]. The diagonal 
line shows the line of identity. [34 with kind permission from Springer Science+Business 
Media B.V].
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Table 1
Input risk variables for FRAX, QFracture and the Garvan assessment tools.
Risk factor FRAX Garvan QFracture Comments
Age + + +
Sex + + +
Height + - +
Weight + +* + * only when BMD is not entered
Ethnicity +* - + *US and Singapore
Previous fragility fracture + +* +** *from the age of 50y
*also number of prior fractures
**prior hip, spine or shoulder
BMD + +* - * site of BMD not specified on website but elsewhere stated to be 
femoral neck
Parental history of hip fracture + - +* * Also, parental history of OP
Smoking +* - +** *current
**categories of exposure
Alcohol intake +* - +** *≥3 units per day
**categories of exposure
Taking steroid tablets regularly +* - + *currently exposed to oral glucocorticoids or has been exposed to 
oral glucocorticoids for more than 3 months at a dose of 
prednisolone of 5mg daily or more
Osteogenesis imperfecta +* - - * grouped as secondary OP
Diabetes +* - +** *Type 1 grouped as secondary OP
** Type 1, type 2
In nursing home - - +
Falls history - +* + *categories of exposure
Dementia - - +
Cancer - - +
Asthma or COPD - - +
Heart attack, angina, stroke or TIA - - +
Chronic liver disease +* - + *grouped as secondary OP
Chronic kidney disease - - +* *stage 4 or 5
Parkinson's disease - - +
Rheumatoid arthritis or SLE +* - + *RA alone
Malabsorption +* - +** *grouped as secondary OP
**Crohn's disease, ulcerative colitis, coeliac disease, steatorrhea or 
blind loop syndrome
Endocrine disorders +* - +** * untreated long-standing hyperthyroidism, hypogonadism
**thyrotoxicosis, hyperparathyroidism, Cushing's syndrome
Premature menopause +* - - * (<45 years) grouped as secondary OP
Epilepsy or taking anticonvulsants - - +
Taking antidepressants - - +
Chronic malnutrition +* - - *grouped as secondary OP
HRT - - +* * oestrogen only
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HRT hormone replacement therapy; OP osteoporosis: SLE systemic lupus erythematosus
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Table 2
Comparative features of the Garvan tool, QFracture and FRAX.
Garvan QFracture FRAX
Externally validated Yes (Canada) Yes (UK only) Yes, internationally
Calibrated No Yes (hip only) Yes
Applicability Uncertain UK 58 countries
Falls as an input variable Yes Yes No
BMD as an input variable Yes* No Yes
Prior fracture as an input variable Yes Yes Yes
Family history as an input variable No Yes Yes
Outcome All fractures excluding digits Hip, forearm, spine, shoulder Hip, forearm, spine, humerus
Outcome metric Incidence Incidence Probability
*
site of BMD not specified on website
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